首页> 外文期刊>Journal of pharmaceutical sciences. >Future Supply Chains Enabled by Continuous Processing-Opportunities and Challenges May 20-21, 2014 Continuous Manufacturing Symposium
【24h】

Future Supply Chains Enabled by Continuous Processing-Opportunities and Challenges May 20-21, 2014 Continuous Manufacturing Symposium

机译:连续加工带来的未来供应链机遇与挑战2014年5月20日至21日,连续制造研讨会

获取原文
获取原文并翻译 | 示例
           

摘要

This paper examines the opportunities and challenges facing the pharmaceutical industry in moving to a primarily continuous processing-based supply chain. The current predominantly large batch and centralized manufacturing system designed for the blockbuster drug has driven a slow-paced, inventory heavy operating model that is increasingly regarded as inflexible and unsustainable. Indeed, new markets and the rapidly evolving technology landscape will drive more product variety, shorter product life-cycles, and smaller drug volumes, which will exacerbate an already unsustainable economic model. Future supply chains will be required to enhance affordability and availability for patients and healthcare providers alike despite the increased product complexity. In this more challenging supply scenario, we examine the potential for a more pull driven, near real-time demand-based supply chain, utilizing continuous processing where appropriate as a key element of a more flow-through operating model. In this discussion paper on future supply chain models underpinned by developments in the continuous manufacture of pharmaceuticals, we have set out; The significant opportunities to moving to a supply chain flow-through operating model, with substantial opportunities in inventory reduction, lead-time to patient, and radically different product assurance/stability regimes. Scenarios for decentralized production models producing a greater variety of products with enhanced volume flexibility. Production, supply, and value chain footprints that are radically different from today's monolithic and centralized batch manufacturing operations. Clinical trial and drug product development cost savings that support more rapid scale-up and market entry models with early involvement of SC designers within New Product Development. The major supply chain and industrial transformational challenges that need to be addressed.
机译:本文探讨了制药业在转向以连续加工为主的供应链方面面临的机遇和挑战。当前为重磅炸弹药品设计的主要是大批量和集中生产系统,已经推动了节奏缓慢,库存繁重的运营模式,这种运行模式越来越被认为是不灵活且不可持续的。确实,新市场和快速发展的技术格局将带动更多产品种类,更短的产品生命周期和更小的药物量,这将加剧本来已经不可持续的经济模式。尽管产品复杂性增加,仍将需要未来的供应链来提高患者和医疗保健提供者的可负担性和可用性。在这种更具挑战性的供应方案中,我们将视情况采用连续拉动作为更流通的运营模型的关键要素,从而研究拉动驱动,近实时基于需求的供应链的潜力。在这份关于未来药品供应链模型的讨论文件中,我们将以药品连续生产的发展为基础进行阐述。转变为供应链直通式运营模式的重大机会,包括减少库存,缩短患者交货时间以及完全不同的产品保证/稳定性制度的大量机会。分散生产模型的场景,可以生产更多种类的产品,并具有更大的批量灵活性。生产,供应和价值链足迹与当今的整体式和集中式批生产操作完全不同。 SC设计人员尽早参与新产品开发,从而节省了临床试验和药品开发成本,从而支持更快速的扩大规模和进入市场的模型。需要解决的主要供应链和工业转型挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号